Gland Pharma Limited has informed the Exchange regarding a press release dated January 07, 2026, titled "Gland Pharma receives approval from the United States Food and Drug Administration (USFDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)".